Search
Iopromide
go.drugbank.com/drugs/DB09156Approved[A260751] Approved by the FDA in 1995 and Health Canada in 1994 under the brand name ULTRAVIST, iopromide is used in radiological diagnosis, including, but not limited to, intra-arterial digital subtraction … It functions as a contrast agent by opacifying blood vessels in the flow path of the contrast agent, permitting radiographic visualization of the internal structures until significant hemodilution occurs
Synonyms: N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-5-[(methoxyacetyl)amino]-N-methylisophthalamideGadodiamide
go.drugbank.com/drugs/DB00225ApprovedInvestigational[A263096] Approved by the FDA in 1993, gadodiamide is the first non-ionic GBCA to be used. … [A263101] However, since linear, non-ionic GBCA is less stable than macrocyclic or ionic GBCA, gadodiamide can potentially lead to more gadolinium retention in the brain and thus more likely to cause side
Telotristat ethyl
go.drugbank.com/drugs/DB12095Approved[A252937] The first line treatment of carcinoid syndrome diarrhea is SSA, but symptoms still reoccur over the course of the disease.[A252937] … [A252937, A252942] Currently, telotristat ethyl is used to treat carcinoid syndrome diarrhea from neuroendocrine tumors that are inadequately controlled by short-acting somatostatin analog (SSA) treatment
Zolmitriptan
go.drugbank.com/drugs/DB00315ApprovedInvestigational[A462, L12978] [Sumatriptan] was the first triptan to be developed, but had poor oral bioavailability and lipophilicity. … [A193797] Zolmitriptan was first approved by the FDA for sale by Zeneca Pharmaceuticals under the trade name Zomig® on November 25, 1997.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromePiflufolastat F 18
go.drugbank.com/drugs/DB14805ApprovedInvestigational[L34319] The images generated by positron emission tomography (PET) are less detailed than those obtained via MRI or CT, but are more sensitive and can reveal cancerous tissue in any area of the body provided … It was first approved by the FDA in May 2021 under the brand name Pylarify and aims to allow for earlier and more accurate detection of suspected prostate cancer metastases or recurrences.
Levoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244083, A29319, L39573] Levoketoconazole was approved by the FDA on December 30, 2021, and is currently marketed under the registered trademark RECORLEV by Xeris Pharmaceuticals, Inc.[L39563] … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying
Betahistine
go.drugbank.com/drugs/DB06698ApprovedInvestigational[A220333,L16403] Betahistine was first approved by the FDA in the 1970s but withdrawn within approximately 5 years due to a lack of evidence supporting its efficacy. … It is currently marketed in Canada by various companies, including Teva Pharmaceuticals.
Synonyms: N-methyl-2-pyridineethanamine, N-methyl-2-(2-pyridinyl)ethanamineProducts: BETAVERT N 8MG, BETAVERT N 16MGIslatravir
go.drugbank.com/drugs/DB15653ApprovedInvestigational[A275490, A275492] Because it is a substrate for deoxycytidine kinase (dCK), its efficacy can be compromised by co-administration with other dCK substrates like lamivudine or emtricitabine, which are consequently … [A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency.
Setmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. … [A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327]
Simethicone
go.drugbank.com/drugs/DB09512ApprovedInvestigational[A228308] It has a favourable safety profile as it is not systemically absorbed.[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308] … Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination.